Abstract

Background: Rheumatoid arthritis (RA) is a joint disorder which affects the quality of life. Early diagnosis and symptomatic treatment can reduce the progression of disease. The treatment is associated with multiple drug therapy for long time. The use of multiple drugs can affect the patient’s economic status. The present study aimed to evaluate the cost-effectiveness of drugs used in the treatment of RA.

Aims and Objectives: The aim of the study was to evaluate the cost of mono and multiple drug therapy in the treatment of RA.

Materials and Methods: The study was conducted in the Department of Pharmacology and Orthopedic of Adichunchanagiri Institute of Medical Sciences, Karnataka for 6 months. A total of 50 patients were screened and 16 patients were included in the study. All the patients were explained study protocol and informed consent was obtained. Data related to age, gender, past history, and type of drug usage were recorded and analyzed. Microsoft Excel and SPSS (20.0) version were used for analysis.

Results: A total of 16 patients were analyzed in the study. The average cost-effective ratio was high for methotrexate and low is hydroxychloroquine. Comparison of cost-effectiveness between different drug combination therapies not showed any significant difference. Combination of non-steroidal anti-inflammatory drugs drug therapy has low cost compared to monoclonal antibody combination therapy.

Conclusion: Methotrexate and hydroxychloroquine combination therapy showed a high cost compared to monotherapy. Combination of low-price drugs can reduce the economic burden on patients.

Key words: Rheumatoid Arthritis; Methotrexate; Hydroxychloroquine; Average Cost Effective Ratio; Diseasemodifying Anti-rheumatoid Drugs; Non-steroidal Anti-inflammatory Drugs; Joint